Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2.

Ding J, Romani J, Zaborski M, MacLeod RA, Nagel S, Drexler HG, Quentmeier H.

PLoS One. 2013 Dec 11;8(12):e83510. doi: 10.1371/journal.pone.0083510.

2.

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG.

J Hematol Oncol. 2011 Feb 7;4:6. doi: 10.1186/1756-8722-4-6.

3.

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.

Okabe S, Tauchi T, Tanaka Y, Kitahara T, Kimura S, Maekawa T, Ohyashiki K.

Cancer Biol Ther. 2014 Feb;15(2):207-15. doi: 10.4161/cbt.26725.

4.

Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.

Wöhrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, Schramek D, Penninger JM, Laßmann S, Werner M, Waller CF, Pahl HL, Zeiser R, Daly RJ, Brummer T.

Leukemia. 2013 Jan;27(1):118-29. doi: 10.1038/leu.2012.222.

PMID:
22858987
5.
6.

Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemia.

Zhang H, Gu L, Liu T, Chiang KY, Zhou M.

PLoS One. 2014 Jun 26;9(6):e100960. doi: 10.1371/journal.pone.0100960.

7.

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.

Weisberg E, Banerji L, Wright RD, Barrett R, Ray A, Moreno D, Catley L, Jiang J, Hall-Meyers E, Sauveur-Michel M, Stone R, Galinsky I, Fox E, Kung AL, Griffin JD.

Blood. 2008 Apr 1;111(7):3723-34. doi: 10.1182/blood-2007-09-114454.

8.

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.

Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, Andreeff M.

Oncotarget. 2015 Oct 13;6(31):30487-99. doi: 10.18632/oncotarget.5890.

9.

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.

Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer BA, Liebermann M, Falkenburg JH, Ruthardt M, Ottmann OG.

PLoS One. 2013 Nov 14;8(11):e80070. doi: 10.1371/journal.pone.0080070.

10.

Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.

Ferri C, Bianchini M, Bengió R, Larripa I.

Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):121-5. doi: 10.1016/j.bcmd.2013.09.002.

PMID:
24091144
11.

ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.

Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA.

Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):47-55. doi: 10.1016/j.bcmd.2014.02.008. Erratum in: Blood Cells Mol Dis. 2015 Dec;55(4):420.

PMID:
24629639
12.

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.

Eiring AM, Page BD, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Colaguori R, Moriggl R, Wilson DJ, Baron R, O'Hare T, Gunning PT, Deininger MW.

Leukemia. 2015 Mar;29(3):586-97. doi: 10.1038/leu.2014.245.

13.

ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.

Airiau K, Mahon FX, Josselin M, Jeanneteau M, Turcq B, Belloc F.

Exp Hematol. 2012 May;40(5):367-78.e2. doi: 10.1016/j.exphem.2012.01.004.

PMID:
22240609
14.
15.

Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.

Salizzato V, Borgo C, Cesaro L, Pinna LA, Donella-Deana A.

Oncotarget. 2016 Apr 5;7(14):18204-18. doi: 10.18632/oncotarget.7569.

16.
17.

The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line.

Xing H, Yang X, Liu T, Lin J, Chen X, Gong Y.

Leuk Res. 2012 Apr;36(4):509-13. doi: 10.1016/j.leukres.2011.12.018.

PMID:
22285507
18.

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.

Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A.

Leukemia. 2005 Oct;19(10):1774-82.

PMID:
16136169
19.

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW.

Cancer Res. 2013 Sep 15;73(18):5775-86. doi: 10.1158/0008-5472.CAN-13-1318.

20.

Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.

Bucur O, Stancu AL, Goganau I, Petrescu SM, Pennarun B, Bertomeu T, Dewar R, Khosravi-Far R.

PLoS One. 2013 Oct 14;8(10):e77390. doi: 10.1371/journal.pone.0077390.

Supplemental Content

Support Center